CA2727792C - Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action - Google Patents

Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action Download PDF

Info

Publication number
CA2727792C
CA2727792C CA2727792A CA2727792A CA2727792C CA 2727792 C CA2727792 C CA 2727792C CA 2727792 A CA2727792 A CA 2727792A CA 2727792 A CA2727792 A CA 2727792A CA 2727792 C CA2727792 C CA 2727792C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
abisilin
acids
composition according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2727792A
Other languages
English (en)
French (fr)
Other versions
CA2727792A1 (en
Inventor
Nina Maksimovna Pinigina
Ludmila Anatolievna Latserus
Anatoly Urievich Baryshnikov
Fania Irshatovna Maganova
Aleksey Mihailovich Kozlov
Zoya Sergeevna Smirnova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "INITIUM-PHARM"
Original Assignee
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "INITIUM-PHARM"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "INITIUM-PHARM" filed Critical OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "INITIUM-PHARM"
Publication of CA2727792A1 publication Critical patent/CA2727792A1/en
Application granted granted Critical
Publication of CA2727792C publication Critical patent/CA2727792C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2727792A 2008-03-14 2008-03-14 Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action Active CA2727792C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2008/000147 WO2009113902A1 (ru) 2008-03-14 2008-03-14 Пpoтивooпyxoлeвaя терпеноидная фармацевтическая композиция «aбиcилин» с ангиогенезингибирующим дeйcтвиeм

Publications (2)

Publication Number Publication Date
CA2727792A1 CA2727792A1 (en) 2009-09-17
CA2727792C true CA2727792C (en) 2017-07-25

Family

ID=41065440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2727792A Active CA2727792C (en) 2008-03-14 2008-03-14 Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action

Country Status (9)

Country Link
US (1) US20110165271A1 (https=)
EP (1) EP2275112A4 (https=)
JP (1) JP2011514354A (https=)
KR (1) KR20110015516A (https=)
CN (1) CN102036672A (https=)
CA (1) CA2727792C (https=)
EA (1) EA017659B1 (https=)
IL (1) IL208092A (https=)
WO (1) WO2009113902A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102657660A (zh) * 2012-04-28 2012-09-12 上海交通大学医学院 三萜类化合物在制备抑制血管生成药物中的应用
WO2013176564A1 (ru) * 2012-05-25 2013-11-28 Общество С Ограниченной Ответственностью "Инитиум-Фарм" Терпеноидное средство для профилактики и лечения атеросклероза и коррекции метаболического синдрома
RU2634253C1 (ru) * 2016-12-22 2017-10-24 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Антиангиогенное лекарственное средство
RU2747147C1 (ru) * 2020-06-22 2021-04-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Фармацевтическая композиция, проявляющая цитотоксичность в отношении клеток карциномы толстой кишки человека
RU2765414C1 (ru) * 2020-09-30 2022-01-31 Ооо "Инитиум-Фарм" Способ стимуляции митофагии и аутофагии в клетках, способ стимуляции аутофагии или митофагии для лечения состояния, ассоциированного с митохондриальной дисфункцией

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051900C1 (ru) 1991-02-15 1996-01-10 Санкио Компани Лимитед 5-амино-1-гидроксиметилциклопентан-1,2,3,4-тетраол, 2-амино-4-гидроксиметил-3a,5,6,6a-тетрагидро-4н-циклопент-[d]-оксазол-4,5,6-триол, их фармацевтически приемлемые соли и способы их получения
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5488116A (en) * 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
RU2054945C1 (ru) 1995-06-28 1996-02-27 Нина Максимовна Пинигина Средство "абисил-1", обладающее противовоспалительной, антибактериальной и ранозаживляющей активностью
RU2196581C2 (ru) 2000-05-04 2003-01-20 Колесников Андрей Григорьевич Способ получения r-тетраола, обладающего противоопухолевой активностью
NZ536196A (en) 2000-06-23 2006-12-22 Schering Ag Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
RU2198653C1 (ru) * 2002-03-29 2003-02-20 Пинигина Нина Максимовна Полиактивные ректальные или вагинальные суппозитории на основе природных терпенов, обогащенных монотерпеноидами, для лечения и/или профилактики урологических, проктологических или гинекологических заболеваний
AU2003264192A1 (en) * 2002-08-30 2004-03-19 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
RU2244928C2 (ru) 2003-02-19 2005-01-20 Пинигина Нина Максимовна Эндогенная фармацевтическая композиция, полученная на основе целенаправленной активации гуморальных медиаторов нервных окончаний коры головного мозга
RU2338547C1 (ru) * 2007-02-16 2008-11-20 Людмила Анатольевна Лацерус Полиактивная терпеноидная субстанция абисил-2, фармацевтическая композиция на ее основе и способы ее применения

Also Published As

Publication number Publication date
IL208092A (en) 2015-07-30
IL208092A0 (en) 2010-12-30
JP2011514354A (ja) 2011-05-06
CN102036672A (zh) 2011-04-27
US20110165271A1 (en) 2011-07-07
WO2009113902A1 (ru) 2009-09-17
CA2727792A1 (en) 2009-09-17
EA017659B1 (ru) 2013-02-28
EP2275112A4 (en) 2011-10-12
EP2275112A1 (en) 2011-01-19
KR20110015516A (ko) 2011-02-16
EA201001289A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
Sharma et al. Review on cancer and anticancerous properties of some medicinal plants
Ateba et al. Natural terpenoids against female breast cancer: a 5-year recent research
Cao et al. Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells
Patocka The chemistry, pharmacology, and toxicology of the biologically active constituents of the herb Hypericum perforatum L
Gupta et al. The genus Calophyllum: review of ethnomedicinal uses, phytochemistry and pharmacology
US9770456B2 (en) Compositions comprising acidic extracts of mastic gum
CA2727792C (en) Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action
Benbacer et al. Antiproliferative effect and induction of apoptosis by Inula viscosa L. and Retama monosperma L. extracts in human cervical cancer cells
Lkhagvasuren et al. Ziyuglycoside II induces caspases-dependent and caspases-independent apoptosis in human colon cancer cells
Latief et al. Potential tracking of cytotoxic activities of mangrove perepate (sonneratia alba) root extract as an anticancer candidate
KR100523562B1 (ko) 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
Klemow et al. Herbal medicine: biomolecular and clinical aspects
Elmosallamy et al. Chemical and Biological Activities of Deverra triradiata Hochst. ex. Boiss. Aerial parts from St. Catherine, Southern Sinai, Egypt.
Wang et al. E. globulus leaf EO exhibits anti-inflammatory effects by regulating GSDMD-mediated pyroptosis, thereby alleviating neurological impairment and neuroinflammation in experimental stroke mice
Uzun et al. Sesquiterpenes and prostate cancer
Hounguè et al. Carissa edulis Vahl (Apocynaceae) extract, a medicinal plant of Benin pharmacopoeia, induces potent endothelium-dependent relaxation of coronary artery rings involving nitric oxide
Woerdenbag et al. Investigation of the anti-tumour action of eupatoriopicrin against the Lewis Lung tumour
Hashemi et al. Apoptosis induced by Viola odorata extract in human glioblastoma multiforme
US20120201903A1 (en) Cytoprotective or therapeutic plant composition
Li et al. Advances of plant-derived natural products in ovarian cancer therapy
KR102434881B1 (ko) 천화분, 백선피 및 상백피를 포함하는 암 및 내성암에 대한 약학적 조성물
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
Kadhim et al. Cytotoxic activities of Ferulago Abbreviata total flavonoid extract on three different cancer cell lines.
Suksamrarn Antiacetylcholinesterase activity of Ventilago denticulata extracts and its chemical constituents
US20060110467A1 (en) Cancer chemotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250303